AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 85 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $92,944 | -47.5% | 320,498 | -18.6% | 0.00% | -100.0% |
| Q4 2022 | $177,098 | +228.0% | 393,638 | +280.0% | 0.00% | – |
| Q3 2022 | $54,000 | -66.2% | 103,589 | -67.2% | 0.00% | -100.0% |
| Q2 2022 | $160,000 | -67.9% | 315,840 | +45.8% | 0.00% | 0.0% |
| Q1 2022 | $498,000 | +62.7% | 216,601 | +235.8% | 0.00% | 0.0% |
| Q4 2021 | $306,000 | +111.0% | 64,511 | +251.9% | 0.00% | – |
| Q1 2021 | $145,000 | -71.3% | 18,332 | -71.5% | 0.00% | -100.0% |
| Q4 2020 | $506,000 | -49.3% | 64,263 | -54.3% | 0.00% | -75.0% |
| Q3 2020 | $998,000 | +31.0% | 140,772 | +70.8% | 0.00% | 0.0% |
| Q2 2020 | $762,000 | +361.8% | 82,427 | +132.7% | 0.00% | +300.0% |
| Q1 2020 | $165,000 | -56.5% | 35,421 | -28.6% | 0.00% | 0.0% |
| Q4 2019 | $379,000 | +11.8% | 49,622 | +0.3% | 0.00% | 0.0% |
| Q2 2019 | $339,000 | +34.5% | 49,458 | +87.5% | 0.00% | 0.0% |
| Q3 2018 | $252,000 | +98.4% | 26,382 | +119.4% | 0.00% | – |
| Q2 2018 | $127,000 | – | 12,026 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |